Lv61
1960 积分 2020-08-12 加入
Efficacy of haploidentical allogeneic hematopoietic cell transplantation following two courses of venetoclax and azacytidine therapy in patients over 55 years old with acute myelogenous leukemia
5天前
已完结
Analysis of CSF3R mutations in atypical chronic myeloid leukemia and other myeloid malignancies
6天前
已完结
CSF3R mutated myeloid neoplasms: Beyond chronic neutrophilic leukemia
6天前
已完结
The clinical characteristics and prognosis of Chinese acute myeloid leukemia patients with CSF3R mutations
6天前
已完结
Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multi-center Cohort Study
6天前
已完结
Pre-emptive therapeutic decisions based on measurable residual disease status in acute myeloid leukemia: ready for prime time?
6天前
已完结
Risk stratification in the clinical application of minimal residual disease assessment in acute myeloid leukemia
6天前
已完结
Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia
6天前
已完结
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
7天前
已完结
Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell transplantation in China: 2024 update
7天前
已完结
皖公网安备34019202002308
